These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1803411)

  • 1. Anti-HIV neutralizing antibodies do not inhibit HIV-induced cell fusion in vitro.
    Emilie D; Delattre RM; Galanaud P; Nicolas JF
    Res Virol; 1991; 142(6):439-42. PubMed ID: 1803411
    [No Abstract]   [Full Text] [Related]  

  • 2. Humoral immunity to the human immunodeficiency virus.
    Weber J
    Curr Opin Immunol; 1989-1990 Feb; 2(3):420-3. PubMed ID: 2483884
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV/AIDS research. Potent HIV antibodies spark vaccine hopes.
    Cohen J
    Science; 2009 Sep; 325(5945):1195. PubMed ID: 19729632
    [No Abstract]   [Full Text] [Related]  

  • 4. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of the Antigenic Variation Working Group.
    Bradac J; Ho D
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1419-21. PubMed ID: 1466971
    [No Abstract]   [Full Text] [Related]  

  • 6. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
    LaCasse RA; Follis KE; Trahey M; Scarborough JD; Littman DR; Nunberg JH
    Science; 1999 Jan; 283(5400):357-62. PubMed ID: 9888845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunopathogenesis of HIV infection.
    Rosenberg ZF; Fauci AS
    Adv Immunol; 1989; 47():377-431. PubMed ID: 2573256
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV vaccines. Magic of the occult?
    Montefiori D; Moore JP
    Science; 1999 Jan; 283(5400):336-7. PubMed ID: 9925493
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies.
    Hansen JE; Sørensen AM; Olofsson S; Osinaga E; Roseto A
    Arch Virol; 1994; 134(1-2):179-84. PubMed ID: 8279954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.
    Zipeto D; Matucci A; Ripamonti C; Scarlatti G; Rossolillo P; Turci M; Sartoris S; Tridente G; Bertazzoni U
    Microbes Infect; 2006 May; 8(6):1424-33. PubMed ID: 16702010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Berkower I; Smith GE; Giri C; Murphy D
    J Exp Med; 1989 Nov; 170(5):1681-95. PubMed ID: 2478654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-1 binding and neutralizing antibodies of injecting drug users.
    Ouverney EP; Teixeira SL; Silva-de-Jesus C; Hacker MA; Morgado MG; Bastos FI; Bongertz V
    Braz J Med Biol Res; 2005 Sep; 38(9):1313-20. PubMed ID: 16138213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.